ERBB2 and cancer: The topoisomerase I inhibitors (e.g., exatecan derivative or DXd) have shown promise in ADC development since the approval of trastuzumab deruxtecan (T-DXd) not only in HER2-high, but HER2-medium or -low human cancers [4].